End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4.7 USD | -7.48% | +1.73% | -13.28% |
Business Summary
Number of employees: 9
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Therapeutics for the Treatment of Non-alcoholic Steatohepatitis and Other Diseases
100.0
%
| 0 | nan % | 2 | 100.0 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | nan % | 2 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
David Happel
CEO | Chief Executive Officer | 62 | 22-10-23 |
George Kemble
CHM | Chairman | 63 | 11-08-14 |
Elizabeth Rozek
CMP | Compliance Officer | 53 | 23-03-31 |
Chief Tech/Sci/R&D Officer | - | 12-12-31 | |
Chief Tech/Sci/R&D Officer | 61 | 21-01-31 | |
Merdad Parsey
BRD | Director/Board Member | 61 | 10-09-29 |
Gaeton Biscardi
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Beth Seidenberg
BRD | Director/Board Member | 67 | 07-03-31 |
Richard Rodgers
BRD | Director/Board Member | 57 | 15-02-28 |
Director/Board Member | 60 | 21-03-31 | |
David Happel
CEO | Chief Executive Officer | 62 | 22-10-23 |
Jinzi Wu
BRD | Director/Board Member | 61 | 19-01-31 |
George Kemble
CHM | Chairman | 63 | 11-08-14 |
Merdad Parsey
BRD | Director/Board Member | 61 | 10-09-29 |
- | - | ||
- | - | ||
- | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 1,520,490 | 0 | 0 | 81.64 % |
Stock B | 1 | 30,393,397 | 26,054,281 ( 85.72 %) | 0 |
Company contact information
Sagimet Biosciences, Inc.
155 Bovet Road Suite 303
94402, San Mateo
+650-561-8600
http://www.sagimet.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.28% | 154M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- SGMT Stock
- Company Sagimet Biosciences Inc.